Adimmune Corporation (TWSE: 4142) today announced that the Company has successfully extended the marketing authorization for its tetanus vaccine and is prepared to commence the steady supply of no less than one million doses annually for the domestic market in Taiwan as early as November 2023.  

Tetanus vaccine can prevent infection caused by Clostridium tetani bacteria, which can lead to neurological disorders such as muscle stiffness and convulsions. This vaccine is particularly vital for individuals who have experienced traumas, car accidents, undergone surgeries, or pregnant women. In such cases, tetanus vaccination stands out as the most effective and reliable method of prevention. 

Tetanus vaccine has faced persistent shortages in Taiwan’s health care system, primarily due to the heavy reliance on imports from India and Southeast Asia. Adimmune's tetanus toxoid, the only tetanus vaccine produced within the country and granted marketing authorization, has the potential to effectively ease the shortage issue in Taiwan. In a world of frequent international turbulence, conflicts, and natural disasters, Adimmune’s independent and stable supply of tetanus vaccine is not only for the safeguard of the health of the public in Taiwan, but also for the national defense and vaccine self-sufficiency.   

Adimmune’s tetanus vaccine is distributed through its subsidiary, Enimmune Corp. (TWSE: 6564). “In 2019, Adimmune invested over NT$300 million in the construction of the state-of-the-art facility dedicated to tetanus vaccine production, ensuring compliance with PICS/GMP and US FDA standards. The construction was completed by the end of 2022, followed by the passing of Taiwan’s GMP inspection in Q1 of 2023 by the Food and Drug Administration of the Ministry of Health and Welfare. After completing the trial run and validation, Adimmune successfully extended the marketing authorization in October 2023,” said Vic Chang, President of Enimmune. “Adimmune’s tetanus plant is the only tetanus vaccine plant in Taiwan and one of the few specialized tetanus vaccine production lines globally. After satisfying the domestic needs in Taiwan for epidemic prevention, Adimmune and Enimmune will together promote our tetanus vaccine to Mainland China, Japan, Korea, Europe and the U.S. markets in the future.”  

In addition, Adimmune expects to upgrade the existing tetanus vaccine to a single syringe package in 2025, which will be more convenient for emergency and clinical use. Since the current tetanus vaccine is mostly available in vials or ampoules, the introduction of a single-dose syringe for the vaccine can eliminate the necessity to open vials for extraction, thus mitigating associated risks.